文献速递淋巴瘤

BET溴结构域抑制剂BAY 1238097治疗淋巴瘤的临床前评价

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
PubMed 文献 · Br J Haematol · 2017-06-27

该临床前研究评价了新型BET抑制剂BAY 1238097在淋巴瘤模型中的抗肿瘤活性:在多种淋巴瘤细胞系中显示抗增殖活性,中位50%抑制浓度为70至208 nmol/l,并在两种弥漫大B细胞淋巴瘤模型中作为单药显示强体内抗肿瘤疗效;基因表达谱显示其靶向NFKB/TLR/JAK/STAT信号通路、MYC和E2F1调控基因等,并与EZH2、mTOR和BTK抑制剂呈体外协同作用。

要点

  • BAY 1238097在淋巴瘤细胞系中显示抗增殖活性,中位50%抑制浓度为70至208 nmol/l。
  • BAY 1238097作为单药在两种弥漫大B细胞淋巴瘤模型中显示强体内抗肿瘤疗效。
  • BAY 1238097与EZH2、mTOR和BTK抑制剂呈体外协同作用。

核心结论

  • BET抑制剂BAY 1238097在体外和体内均表现出有前景的抗淋巴瘤临床前活性,其作用通过干扰驱动淋巴瘤细胞的生物学过程介导。
  • 数据提示可考虑靶向EZH2、mTOR和BTK联合BET溴结构域的联合方案。

研究设计与样本

  • 临床前研究,在淋巴瘤衍生细胞系 panel 和两种弥漫大B细胞淋巴瘤体内模型中评价BAY 1238097的抗肿瘤活性,并进行基因表达谱分析。

主要发现

  • BAY 1238097在大量淋巴瘤衍生细胞系中显示抗增殖活性,中位50%抑制浓度为70至208 nmol/l。
  • BAY 1238097作为单药在两种弥漫大B细胞淋巴瘤模型中显示强体内抗肿瘤疗效。
  • 基因表达谱显示BAY 1238097靶向NFKB/TLR/JAK/STAT信号通路、MYC和E2F1调控基因、细胞周期调控和染色质结构。
  • BAY 1238097的基因表达谱特征与其他BET溴结构域抑制剂获得的特征高度重叠,与HDAC抑制剂、mTOR抑制剂和去甲基化药物部分重叠。
  • BAY 1238097在体外与EZH2、mTOR和BTK抑制剂呈协同作用。

关键数值与推荐

  • BAY 1238097在淋巴瘤衍生细胞系中的中位50%抑制浓度为70至208 nmol/l。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bernasconi E, Gaudio E, Lejeune P, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017. PMID: 28653353. doi:10.1111/bjh.14803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。